Impact Biomedical (IBO) Capital Expenditures (2023)
Impact Biomedical's (IBO) quarterly Capital Expenditures came in at $1000.0 in Q3 2023, down 91.67% quarter-over-quarter from $12000.0 in Q2 2023.
Powered by 
Analysis
Impact Biomedical (IBO) Capital Expenditures (2023) Analysis & Trends
Impact Biomedical (IBO) has reported Capital Expenditures for 1 consecutive years, with $1000.0 the latest figure, recorded in Q3 2023.
- For the quarter ending Q3 2023, Capital Expenditures changed N/A year-over-year to $1000.0; the trailing twelve-month figure through Dec 2023 stood at $18000.0 (changed N/A YoY), and the FY2023 full-year result was $18000.0, down 93.48% from the prior year.
- Capital Expenditures fell to $1000.0 in Q3 2023 per IBO's latest filing, from $12000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $12000.0 in Q2 2023 and bottomed at $1000.0 in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 513.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 140.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 112.20 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 240.20 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 37.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 40.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -1.87 Mn |
| 10 | Impact Biomedical | 49.63 Mn | 49.62 Mn | 2,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 12,000.00 |
| Mar 31, 2023 | 5,000.00 |